Physician profile
James Otting
NPI 1497953749
$46,989.75
in general payments reported to CMS, 2019-2025
51 companies · $2,875 in 2025
The $2,875 reported for 2025 was more than what 84% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,866 · 2020: $6,217 · 2021: $17K · 2022: $2,775 · 2023: $12K · 2024: $3,142 · 2025: $2,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,050 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,400 · Travel and Lodging: $4,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,050.47 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,400.00 |
| Travel and Lodging | $4,864.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $23,783.87 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, General - Pain Management |
| Medtronic, INC. | $4,255.72 | 2021-2024 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Osteocool Rf Ablation System |
| Nutech Spine, INC. | $3,935.98 | 2020-2021 | |
| Saluda Medical Americas, INC. | $2,641.50 | 2023-2025 | Evoke, Evoke Scs |
| Nevro Corp. | $1,027.19 | 2019-2024 | Senza |
| Teva Pharmaceuticals USA, INC. | $1,023.10 | 2019-2023 | Ajovy |
| Amgen INC. | $1,017.35 | 2019-2022 | |
| Abbott Laboratories | $975.48 | 2019-2023 | Proclaim |
| Collegium Pharmaceutical, INC. | $887.83 | 2019-2024 | Xtampza |
| Scilex Pharmaceuticals INC. | $798.90 | 2019-2024 | Ztlido |
| Abbvie INC. | $731.01 | 2021-2023 | |
| Allergan, INC. | $691.23 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $530.82 | 2019-2024 | Relistor |
| Pfizer INC. | $433.44 | 2019-2024 | |
| Protega Pharmaceutials INC | $392.50 | 2022-2024 | Roxybond |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Otting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.